TNDM - タンデム・ダイアベティス・ケア （Tandem Diabetes Care Inc.）

Pacer Advisors Inc. increased its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) by 69.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,328 shares of the medical device company’s stock after buying an additional 5,062 shares […]

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating)’s share price gapped down prior to trading on Thursday after Stifel Nicolaus lowered their price target on the stock from $45.00 to $40.00. The stock had previously closed at $39.95, but opened at $35.18. Tandem Diabetes Care shares last traded at $36.51, with a volume of 329,418 […]

Tandem Diabetes Care Inc (NASDAQ: TNDM ) shares are down Thursday morning as its Q1 results missed Street expectations. TNDM reported Q1 FY23 sales of $169.39 million , missing the consensus of $170.23 million. The automated insulin delivery technology maker posted adjusted losses of $(40.4) million, compared to a loss of $(14.7) million a year ago. Adjusted EPS loss of $(0.63) missed the Street view of $(0.52). The worldwide installed base … Full story available on Benzinga.com

Tandem Diabetes Care, Inc. (NASDAQ:NASDAQ:TNDM) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsSusan Morrison - Executive Vice President and Chief Administrative…

Tandem Diabetes Care (NASDAQ: TNDM ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Tandem Diabetes Care missed estimated earnings by 21.15%, reporting an EPS of $-0.63 versus … Full story available on Benzinga.com

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-71-at-barclays-432SI-3013601

Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 FY22 sales of $220.50 million , missing the consensus of $221.83 million. The automated insulin delivery technology maker posted adjusted losses of $(0.46) million, compared to an income of $10.81 million a year ago. Tandem … Full story available on Benzinga.com

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-40-at-baird-432SI-3011879

https://www.investing.com/news/pro/tandem-diabetes-care-pt-lowered-to-50-at-piper-sandler-432SI-3011822

Tandem Diabetes Care, Inc. (NASDAQ:NASDAQ:TNDM) Q4 2022 Earnings Conference Call February 22, 2023 4:30 PM ETCompany ParticipantsSusan Morrison - EVP & Chief Administrative OfficerJohn…

As of Wednesday, Tandem Diabetes Care Inc.’s (NASDAQ:TNDM) stock closed at $42.52, up from $41.54 the previous day. While Tandem Diabetes Care Inc. has overperformed by 2.36%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNDM fell by -71.69%, with highs and lows ranging from $155.86 […]

Tandem Diabetes Care Inc (NASDAQ: TNDM ) has agreed to acquire AMF Medical SA , the privately held Swiss developer of the investigational Sigi Patch Pump. It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through … Full story available on Benzinga.com

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it acquired AMF Medical, maker of the Sigi patch pump for insulin delivery. Switzerland-based AMF Medical currently develops the Sigi patch pump and does not offer it commercially. The system received FDA breakthrough device designation just over one year ago. AMF Medical designed Sigi as an ergonomic, rechargeable […] The post Tandem Diabetes Care to acquire patch pump maker AMF Medical appeared first on Drug Delivery Business .

Tandem Diabetes Care (TNDM) has agreed to acquire Swiss insulin patch pump developer, AMF Medical for CHF 62.4M in cash due at closing.The agreement covers a previous strategic…

Tandem Diabetes Care Inc. , an insulin delivery and diabetes technology company, said Tuesday it has entered a definitive agreement to acquire AMF Medical SA, a Swiss privately held maker of the Sigi Patch Pump. The pump is currently under development and is not commercially available. "It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology," the San Diego-based Tandem said in a statement. Tandem will pay 62.4 million Swiss francs ($66.4 million) upon closing, as well as a previous investment of 8 million Swiss francs, and up to 129.6 million francs of earnout payments upon achievement of certain milestones. The deal is expected to close in January. Tandem stock was not active premarket, but has fallen 71% in the year to date, while the S&P 500 has fallen 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.